Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
- Conditions
- Esophageal CancerGastric Cancer
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2023-03-16
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02954536
- Locations
- 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Study of BMS-986012 in Subjects With Small Cell Lung Caner
- Conditions
- Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2019-08-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 7
- Registration Number
- NCT02949895
- Locations
- 🇯🇵
Local Institution, Chuo-ku, Tokyo, Japan
Combination of Platinum Doublets and Hypofractionated Radiotherapy in NSCLC
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2017-11-30
- Lead Sponsor
- The Netherlands Cancer Institute
- Registration Number
- NCT02947113
Gemcitabine Hydrochloride, Cisplatin, and AGS-003-BLD in Treating Patients With Muscle-Invasive Bladder Cancer Undergoing Surgery
- Conditions
- Stage III Bladder Urothelial CarcinomaInfiltrating Bladder Urothelial CarcinomaStage II Bladder Urothelial CarcinomaStage IV Bladder Urothelial Carcinoma
- Interventions
- Drug: CisplatinDrug: Gemcitabine HydrochlorideProcedure: Radical CystectomyBiological: Tumor Cell-Derived Vaccine Therapy
- First Posted Date
- 2016-10-25
- Last Posted Date
- 2017-11-17
- Lead Sponsor
- Mayo Clinic
- Registration Number
- NCT02944357
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
A Study of LY3200882 in Participants With Solid Tumors
- Conditions
- Solid Tumor
- Interventions
- Drug: LY3200882Drug: CisplatinDrug: LY3300054Drug: GemcitabineDrug: nab-PaclitaxelRadiation: Intensity Modulated Radiotherapy
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 223
- Registration Number
- NCT02937272
- Locations
- 🇦🇺
St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
🇦🇺Greenslopes Private Hospital, Greenslopes, Queensland, Australia
🇫🇷CHRU de Lille, Lille, France
Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Biological: PembrolizumabDrug: CisplatinDrug: CarboplatinDrug: EtoposideRadiation: Radiation therapy
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 5
- Registration Number
- NCT02934503
- Locations
- 🇺🇸
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer
- Conditions
- Oral Cavity Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Target Recruit Count
- 224
- Registration Number
- NCT02923258
- Locations
- 🇨🇳
Shanghai ninth people's hospital, Shanghai, Shanghai, China
Concurrent Chemotherapy Based on Genetic Testing in Patients With High-Risk Salivary Gland Tumors
- Conditions
- Salivary Gland TumorsHead and Neck Cancer
- Interventions
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2018-03-20
- Lead Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- Target Recruit Count
- 20
- Registration Number
- NCT02921984
- Locations
- 🇨🇳
Shanghai ninth people's hospital, Shanghai, Shanghai, China
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression
- Conditions
- Carcinoma, Non-Small-Cell LungSecondaryAdvanced Stage IIIBHigh Thymidylate Synthase Expression
- Interventions
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
- Target Recruit Count
- 2
- Registration Number
- NCT02919462
- Locations
- 🇮🇹
U.O. Oncologia Medica, Faenza, RA, Italy
🇮🇹U.O. Oncologia Ospedale degli Infermi, Rimini, Italy
🇮🇹Ircc Irst, Meldola, FC, Italy
Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer
- Conditions
- Oropharynx Cancer
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 228
- Registration Number
- NCT02908477
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Rochester, Rochester, Minnesota, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.